Proposal for a noradrenaline hypothesis of schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 28, Issue 5, 2004, Pages 913-922

  Yamamoto, Kenichi ^a   Hornykiewicz, Oleh ^b  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

BPRS; Brief Psychiatric Rating Scale; CA; catecholamine; central nervous system; cerebrospinal fluid; CNS; Comprehensive Psychopathological Rating Scale; CPRS; CSF; DA; DBH; dopamine; Negative symptoms; Noradrenaline; Pathogenesis; Positive symptoms; Schizophrenia

Indexed keywords

NORADRENALIN;

BLOOD ANALYSIS; BLOOD SAMPLING; BRAIN BLOOD FLOW; BRAIN DEVELOPMENT; BRAIN FUNCTION; BRAIN METABOLISM; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; ELECTROENCEPHALOGRAM; EYE MOVEMENT; HUMAN; HYPOTHESIS; NERVE CELL DIFFERENTIATION; NERVE CELL NETWORK; NORADRENERGIC SYSTEM; PATHOGENESIS; REVIEW; SCHIZOPHRENIA; SLEEP;

ANIMALS; BRAIN; HUMANS; NOREPINEPHRINE; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 4444341672     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2004.05.033     Document Type: Review

References (128)

1. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L.S., Weiss R., Cooper T.B., Mann J.J., Van Heertum R.L., Gorman J.M., Laruelle M. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 97:2000;8104-8109
2. Adams L.M., Geyer M.A. Effects of 6-hydroxydopamine lesions of locus coeruleus on startle in rats. Psychopharmacology. 73:1981;394-398
3. Amaral D.G., Sinnamon H.M. The locus coeruleus: neurobiology of a central noradrenergic nucleus. Prog. Neurobiol. 9:1977;147-196
4. Andreasen N., Olsen S., Dennert J.W., Smith M.R. Ventricular enlargement in schizophrenia: relationship to positive and negative symptoms. Am. J. Psychiatry. 139:1982;297-302
5. Andreasen N.C., Rezai K., Alliger R., Swayze V.W., Flaum M., Kirchner P., Cohen G., O'Leary D.S. Hypofrontality in neuroleptic-naïve patients and in patients with chronic schizophrenia. Arch. Gen. Psychiatry. 49:1992;943-958
6. Angrist B., Rotrosen J., Gershon S. Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology. 72:1980;17-19
7. Angrist B., Peselow E., Rubinstein M., Corwin J., Rotrosen J. Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology. 78:1982;128-150
8. Åsberg M., Montgomery S.A., Perris C., Schalling P., Sedvall G. Comprehensive psychopathological rating scale. Acta Psychiatr. Scand., Suppl. 271:1978;5-27
9. Aston-Jones G., Bloom F.E. Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J. Neurosci. 1:1981;876-886
10. Baldessarini R.J., Frankenburg F.R. Clozapine. A novel antipsychotic agent. N. Engl. J. Med. 324:1991;746-754
11. Bartfai A., Edman G., Levander S.E., Schalling D., Sedvall G. Bilateral skin conductance activity, clinical symptoms and CSF monoamine metabolite levels in unmedicated schizophrenics, differing in rate of habituation. Biol. Psychol. 18:1984;201-218
12. Beleslin D.B., Samardzic R., Krstic S.K., Micic D., Terzic B. Comparison of behavioral changes in cats treated with intracerebro-ventricular 6-hydroxydopamine and reserpine. Brain Res. Bull. 6:1981;285-287
13. Berman K.F., Weinberger D.R., Shelton R.C., Zec R.F. A relationship between anatomical and physiological brain pathology in schizophrenia: lateral cerebral ventricular size predicts cortical blood flow. Am. J. Psychiatr. 144:1987;1277-1282
14. Bird E.D., Spokes E.C.G., Iversen L.L. Dopamine and noradrenaline in post-mortem brain in Huntington's disease and schizophrenic illness. Acta Psychiatr. Scand. (Suppl. 280):1980;63-73
15. Bolme P., Forsyth R.P., Ishizaki T., Melmon K.L. Hemodynamic effects of systemic and central administration of clonidine in the monkey. Am. J. Physiol. 228:1975;1276-1279
16. Bondy B., Ackenheil M., Birzle W., Elbers R., Frohler M. Catecholamines and their receptors in blood: evidence for alterations in schizophrenia. Biol. Psychiatry. 19:1984;1377-1393
17. Brady K.T., Lydiard R.B., Malcolm R., Ballenger J.C. Cocaine-induced psychosis. J. Clin. Psychiatry. 52:1991;509-512
18. Brenner R., Shopsin B. The use of monoamine oxidase inhibitor in schizophrenia. Biol. Psychiatry. 15:1980;633-647
19. Bridge T.P., Kleinman J.E., Karoum F., Wyatt R.J. Postmortem central catecholamines and antemortem cognitive impairment in elderly schizophrenics and controls. Neuropsychobiology. 14:1985;57-61
20. Bunsey M.D., Strupp B.J. Specific effects of idazoxan in a distraction task: evidence that endogenous norepinephrine plays a role in selective attention in rats. Behav. Neurosci. 109:1995;903-911
21. Carlsson A. The impact of catecholamine research in medical science and practice. Usdin E., Kopin I.J., Barchas J. Catecholamines: Basic and Clinical Frontiers. 1979;4-19 Pergamon, New York
22. Chouinard G., Pinard G., Prenoveau Y., Tetreaurlt L. Alpha methyldopa-chlorpromazine interaction in schizophrenia patients. Curr. Ther. Res. 15:1973;60-72
23. Cross A.J., Crow T.J., Killpack W.S., Longden A., Owen F., Riley G.J. The activities of brain dopamine-β-hydroxylase and catechol-o-methyl transferase in schizophrenics and controls. Psychopharmacology. 59:1978;117-121
24. Crow T.J. Molecular pathology of schizophrenia: more than one disease process? Br. Med. J. 280:1980;66-68
25. Crow T.J., Baker H.F., Cross A.J., Joseph M.H., Lofthouse R., Longden A., Owen F., Filey G.J., Glover V., Killpack W.S. Monoamine mechanisms in chronic schizophrenia: post mortem neurochemical findings. Br. J. Psychiatry. 134:1979;249-256
26. Csernansky J.G., Kaplan J., Hollister L.E. Problems in classification of schizophrenics as neuroleptic responders and nonresponders. J. Nerv. Ment. Dis. 173:1985;325-331
27. Dajas F., Barbeito L., Martinez-Pesquera G., Lista A., Puppo D., Puppo-Touriz H. Plasma noradrenaline and clinical psychopathology in schizophrenia. A correlation analysis. Neuropsychobiology. 10:1983;70-74
28. De Sarro G.B., Ascioti C., Froio F., Libri V., Nistico G. Evidence that locus coeruleus is the site where clonidine and drugs acting at alpha 1- and alpha 2-adrenoceptors affect sleep and arousal mechanisms. Br. J. Pharmacol. 90:1987;675-685
29. Elam M., Thoren P., Svensson T.H. Locus coeruleus neurons and sympathetic nerves: activation by visceral afferents. Brain Res. 375:1986;117-125
30. Farley I.J., Price K.S., Hornykiewicz O. Monoaminergic systems in the human limbic brain. Livingston K.E., Hornykiewicz O. Limbic Mechanisms. 1978;333-349 Plenum, New York
31. Farley I.J., Price K.S., McCullough E., Deck J.H.N., Hordynski W., Hornykiewicz O. Norepinephrine in chronic paranoid schizophrenia: above-normal levels in limbic forebrain. Science. 200:1978;456-458
32. Feenstra M.G., Vogel M., Botterblom M.H., Joosten R.N., de Bruin J.P. Dopamine and noradrenaline efflux in the rat prefrontal cortex after classical aversive conditioning to an auditory cue. Eur. J. Neurosci. 13:2001;1051-1054
33. Foote S.L., Morrison J.H. Extrathalamic modulation of cortical function. Annu. Rev. Neurosci. 10:1987;67-95
34. Foote S.L., Aston-Jones G., Bloom F.E. Impulse activity of locus coeruleus neurons in awake rats and monkeys is a function of sensory stimulation and arousal. Proc. Natl. Acad. Sci. U. S. A. 77:1980;3033-3037
35. Freedman R., Kirch D., Bell J., Adler L.E., Pecerich M., Pachtman E., Renuer P. Clonidine treatment of schizophrenia. Double-blind comparison to placebo and neuroleptic drugs. Acta Psychiatr. Scand. 65:1982;35-45
36. Galvez R., Mesches M.H., McGaugh J.L. Norepinephrine release in the amygdala in response to footshock stimulation. Neurobiol. Learn. Mem. 66:1996;253-257
37. Gattaz W.F., Riederer P., Reynolds G.P., Gattaz D., Beckmann H. Dopamine and noradrenaline in the cerebrospinal fluid of schizophrenic patients. Psychiatry Res. 8:1983;243-250
38. Gay N., Cottraud J.A., Denoroy L., Tommasi M., Kopp N. Possible increase of dopamine-beta-hydroxylase activity in the locus ceruleus of paranoid schizophrenic patients: a preliminary post-mortem study. Psychiatry Res. 27:1989;31-38
39. Glazer W.M., Charney D.S., Heninger G.R. Noradrenergic function in schizophrenia. Arch. Gen. Psychiatry. 44:1987;898-904
40. Gomes U.C.R., Shanley B.C., Potggieter L., Roux J.T. Noradrenergic overactivity in chronic schizophrenia: evidence based in cerebrospinal fluid noradrenaline and cyclic nucleotide concentrations. Br. J. Psychiatry. 137:1980;346-351
41. Gruzelier J.H., Venables P.H. Evidence of high and low level of physiological arousal in schizophrenics. Psychophysiology. 12:1975;6-73
42. Hartmann E. Schizophrenia: a theory. Psychopharmacology. 49:1976;1-15
43. Hazlett E.A., Dawson M.E., Buchsbaum M.S., Nuechterlein K.H. Reduced regional brain glucose metabolism assessed by positron emission tomography in electrodermal nonresponder schizophrenics: a pilot study. J. Abnorm. Psychology. 102:1993;39-46
44. Hobson J.A., McCarley R.W., Wyzinski P.W. Sleep cycle oscillation: reciprocal discharge by two brainstem neuronal groups. Science. 189:1975;55-58
45. Holmberg G., Gershon S. Autonomic and psychic effects of yohimbine hydrochloride. Psychopharmacology. 2:1961;93-106
46. Holzman P.S., Proctor L.R., Hugens D.W. Eye tracking patterns in schizophrenia. Science. 181:1973;179-181
47. Holzman P.S., Levy D.L., Proctor L.R. Smooth pursuit eye movements, attention and schizophrenia. Arch. Gen. Psychiatry. 33:1976;1415-1420
48. Hornykiewicz O. Brain catecholamines in schizophrenia - a good case for noradrenaline. Nature. 299:1982;484-486
49. Hornykiewicz O. Brain noradrenaline and schizophrenia. Prog. Brain Res. 65:1986;29-39
50. Hörtnagl H., Schlögl E., Sperk G., Hornykiewicz O. The topographical distribution of the monoaminergic innervation in the basal ganglia of the human brain. Prog. Brain Res. 58:1983;269-274
51. Iversen L.L., Iversen S.D., Snyder S.H. Handbook of Psychopharmacology. vol. 8:1977;Plenum, New York
52. Janowsky D.S., E1-Yousef M.K., Davis J.M., Sekerke H.J. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch. Gen. Psychiatry. 28:1973;185-191
53. Johnstone E.C., Crow T.J., Frith C.D., Carney M.W.P., Price J.S. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet. 1:1978;848-851
54. Kaneko M., Honda K., Kanno T., Horikoshi R., Manoe T., Watanabe A., Kumashiro H. Plasma free 3-methoxy-4-hydroxyphenylglycolin acute schizophrenics before and after treatment. Neuropsychobiology. 25:1992;126-129
55. Kay S.R., Opler L.A. L-dopa in the treatment of negative schizophrenic symptoms: a single-subject experimental study. Int. J. Psychiatry Med. 15:1985;293-298
56. Kay S.R., Fiszbein A., Olper L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13:1987;261-276
57. Kemali D., DelVeccio M., Maj M. Increased noradrenaline levels in CSF and plasma of schizophrenic patients. Biol. Psychiatry. 17:1982;711-717
58. Kemali D., Maj M., Iorio G., Marcinao F., Nalfe G., Galderisi S., Salvati A. Relationship between CSF noradrenaline levels, C-EEG indicators of activation and psychosis ratings in drug-free schizophrenic patients. Acta Psychiatr. Scand. 71:1985;19-24
59. Kemali D., Maj M., Galderisi S., Ariano M.G., Starace F. Factors associated with increased noradrenaline levels in schizophrenic patients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 14:1990;49-59
60. Kety S. The biogenic amines in the central nervous system: their possible roles in arousal, emotion, and learning. Schmitt F.O. The Neurosciences, 2nd Study Program. 1970;324-336 Rockefeller Univ. Press, New York
61. Kim D.K., Shin Y.M., Kim C.E., Cho H.S., Kim Y.S. Electrodermal responsiveness, clinical variables, and brain imaging in male chronic schizophrenics. Biol. Psychiatry. 33:1993;786-793
62. Kleinman J.E., Bridge O., Karoum F., Speciale S., Staub R., Zalcman S., Gillin J.C., Wyatt R.J. Catecholamines and metabolites in the brains of psychotics and normals: post-mortem studies. Usdin E., Kopin I.J., Barchas J. Catecholamines: Basic and Clinical Frontiers. vol. 2:1979;1845-1847 Pergamon, New York
63. Ko G.N., Jimerson D.C., Wyatt R.J., Bigelow L.B. Plasma 3-methoxy-4-hydroxy-phenyl-glycol changes associated with clinical state and schizophrenic subtype. Arch. Gen. Psychiatry. 45:1988;842-846
64. Kokkinidis L., Anisman H. Involvement of norepinephrine in startle arousal after acute and chronic D-amphetamine administration. Psychopharmacology. 59:1978;285-292
65. Kramer M.S., Vogel W.H., Di Johnson C., Dewey D.A., Sheves P., Cavicchia S., Little P., Schmidt R., Kimes I. Anti-depressants in 'depressed' schizophrenic inpatients. Arch. Gen. Psychiatry. 46:1989;922-928
66. Kupfer D.J., Wyatt R.J., Scott J., Snyder F. Sleep disturbance in acute schizophrenia patient. Am. J. Psychiatry. 126:1970;1213-1223
67. Lader M.H. Comparison of amphetamine sulfate and caffeine citrate in man. Psychopharmacology. 14:1969;83-94
68. Lake C.R., Sternberg D.E., van Kammen D.P., Ballenger J.C., Ziegler M.G., Post R.M., Kopin I.J., Bunney W.E. Schizophrenia: elevated cerebrospinal fluid norepinephrine. Science. 207:1980;331-333
69. Lauder J.M., Krebs H. Do neurotransmitters, neurotumors, and hormones specify critical periods? Greenough W.T., Juraska J.M. Developmental Neuropsychobiology. 1986;119-174 Academic Press, Orlando, FL
70. Laverty R. On the roles of dopamine and noradrenaline in animal behaviours. Prog. Neurobiol. 3:1974;31-70
71. Levy D.L., Lajonchere C.M., Dorogusker B., Min D., Lee S., Tartaglini A., Lieberman J.A., Mendel N.R. Quantitative characterization of eye tracking dysfunction in schizophrenia. Schizophr. Res. 42:2000;171-185
72. Lieberman J.A., Koreen A.R. Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophr. Bull. 19:1993;371-429
73. 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study. J. Clin. Psychopharmacol. 13:1993;264-267
74. Maas J.W. Relationships between central nervous system noradrenergic function and plasma and urinary concentrations of norepinephrine metabolites. Adv. Biochem. Psychopharmacol. 39:1984;45-55
75. Maina G., Barzega G., Bellino S., Bogetto F., Rarizza L. Type I and type II schizophrenia: relations between tonic electrodermal activity and clinical ratings before and after haloperidol treatment. Psychiatry Res. 57:1995;49-56
76. McGlashan T.H., Hoffman R.E. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch. Gen Psychiatry. 57:2000;637-648
77. Moore R.Y., Bloom F.E. Central catecholamine neuron systems: Anatomy and physiology of the norepinephrine and epinephrine systems. Annu. Rev. Neurosci. 2:1979;113-168
78. Nakata T., Berard W., Kogosov E., Alexander N. Cardiovascular change and hypothalamic norepinephrine release in response to environmental stress. Am. J. Physiol. 264:1993;R784-789
79. Nyback H., Berggren B.-M., Hindmarsh T., Sedvall G., Wiesel F.-A. Cerebroventricular size and cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy volunteers. Psychiatry Res. 9:1983;301-308
80. Overall J.E., Gorham D.R. Brief Psychiatric Rating Scale. Psychol. Rep. 10:1962;799-812
81. Owens D.G.C., Johnstone E.C. The disabilities of chronic schizophrenia - their nature and the factors contributing to their development. Br. J. Psychiatry. 136:1980;384-395
82. Panse F., Klages W. Klinishe-psychopathologische Beobachtungen bei chronishem Missbranch von Ephedrine and verwandtem Substanzen. Arch. Psychiatr. Zeitshr. Ges. Neurol. 206:1964;69-95
83. Pifl Ch., Schingnitz G., Hornykiewicz O. Effect of 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience. 44:1991;591-605
84. Post R.M., Fink Ed., Carpenter W.T. Jr., Goodwin F.K. Cerebrospinal fluid amine metabolites in acute schizophrenia. Arch. Gen. Psychiatry. 32:1975;1063-1068
85. Rasmussen K., Jacobs B.L. Single unit activity of locus coeruleus neurons in the freely moving cat: II. Conditioning and pharmacologic studies. Brain Res. 371:1986;335-344
86. Redmond D.E., Hinrichs R.L., Maas J.W., Kling A. Behavior of free-ranging macaques after intraventricular 6-hydroxydopamine. Science. 181:1973;1256-1258
87. Ren Z.G., Pörzgen P.P., Youn Y.-H., Sieber-Blum M. Ubiquitous embryonic expression of the norepinephrine transporter. Dev. Neurosci. 25:2003;1-13
88. Ross D.E., Thaker G.K., Buchanan R.W., Kirkpatrick B., Lahti A.C., Medoff D., Bartko J.J., Goodman J., Tien A. Eye tracking disorder in schizophrenia is characterized by specific ocular motor defects and is associated with the deficit syndrome. Biol. Psychiatry. 42:1997;781-796
89. Saletu B., Küfferle B., Anderer P., Grünberger J., Steinberger K. EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms. Eur. Neuropsychopharmacol. 1:1990;27-36
90. Sato M., Chen C.C., Akiyama K., Otsuki S. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol. Psychiatry. 18:1983;429-440
91. Serper M.R., Chou C.Y., Allen M.H., Czobor P., Cancro R. Symptomatic overlap of cocaine intoxication and acute schizophrenia at emergency presentation. Schizophr. Bull. 25:1999;387-394
92. Sibersweig D.A., Stern E., Frith C., Cahill C., Holmes A., Grootoonk S., Steaward J., McKenna P., Chua S.E., Schnorr L., Jones T., Frackowiak R.S.J. A functional neuroanatomy of hallucinations in schizophrenia. Nature. 378:1995;176-179
93. Siris S.G., Bermanzohn P.C., Gonzalez A., Mason S.E., White C.V., Shuwall M.A. The use of antidepressants for negative symptoms in a subset of schizophrenic patients. Psychopharmacol. Bull. 27(3):1991;331-335
94. Shannak K.S., Hornykiewicz O. Brain monoamines in the rhesus monkey during long-term neuroleptic administration. Adv. Biochem. Psychopharmacol. 24:1980;315-323
95. Stein L., Wise C.D. Possible etiology of schizophrenia: progressive damage to the noradrenergic reward system by 6-hydroxydopamine. Science. 171:1971;1032-1036
96. Sternberg D.E., van Kammen D.P., Lake C.R., Ballenger J.C., Marder S.R., Bunney W.E. The effect of pimozide on CSF norepinephrine in schizophrenia. Arch. Gen. Psychiatry. 138:1981;1045-1051
97. Sternberg D.E., van Kammen D.P., Lerner P., Ballenger J.C., Marder S.R., Post R.M., Bunney W.E. Jr. CSF dopamine β-hydroxylase in schizophrenia. Arch. Gen. Psychiatry. 40:1983;743-747
98. Svensson T.H. Peripheral, autonomic regulation of locus coeruleus noradrenergic neurons in brain: putative implications for psychiatry and psychopharmacology. Psychopharmacology. 92:1987;1-7
99. Svensson T.H. α-Adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 27:2003;1145-1158
100. Sweeney J.A., Haas G.L., Li S., Weiden P.J. Selective effects of antipsychotic medications on eye-tracking performance in schizophrenia. Psychiatry Res. 54:1994;185-198
101. Tanaka T., Yokoo H., Mizoguchi K., Yoshida M., Tsuda A., Tanaka M. Noradrenaline release in the rat amygdala is increased by stress: studies with intracerebral microdialysis. Brain Res. 544:1991;174-176
102. Tandon R., DeQuardo J.R., Taylor S.F., McGrath M., Jibson M., Eiser A., Goldman M. Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome. Schizophr. Res. 45:2000;191-201
103. Thierry A.M., Javoy F., Glowinsky J., Kety S.S. Effects of stress on the metabolism of norepinephrine, dopamine and serotonin in the central nervous system of the rat: I. Modification of norepinephrine turnover. J. Pharmacol. Exp. Ther. 163:1968;163-171
104. Tomiyama G. Chronic schizophrenia-like states in methamphetamine psychosis. Jpn. J. Psychiatry Neurol. 44:1990;531-539
105. Van Kammen D.P., Gelernter J. Biochemical instability in schizophrenia: I. The norepinephrine system. Meltzer H.Y. Psychopharmacology: The Third Generation of Progress. 1987;745-751 Raven Press, New York
106. Van Kammen D.P., Mann L.S., Sternberg D.E., Scheimin M., Ninan P.T., Marder S.R., Van Kammen W.B., Rieder R.O., Linnolia M. Dopamine-β- hydroxylase activity and homovanillic acid in spinal fluid of schizophrenics with brain atrophy. Science. 220:1983;974-976
107. Van Kammen D., Peters J.L., Yao J., van Kammen W.B., Neylan T., Shaw D. Noradrenergic mechanisms, state dependency and negative symptoms in schizophrenia. Greden J.F., Tanden R. Negative Schizophrenic Symptoms: Pathophysiology and Clinical Implications. 1991;113-130 American Psychiatric Press, Washington
108. Weickert C.S., Weinberger D.R. A candidate molecule approach defining developmental pathology in schizophrenia. Schizophr. Bull. 24:1998;303-316
109. Weinberger D.R., Bigelow C.B., Kleinman J.E., Klein S.T., Rosenblatt J.E., Wyatt R.J. Cerebral ventricular enlargement in chronic schizophrenia on association with a poor response to treatment. Arch. Gen. Psychiatry. 37:1980;11-13
110. Weiss E.R., Maness P., Lauder J.M. Why do neurotransmitters act like growth factors? Prog. Dev. Neurobiol. 5:1998;323-335
111. Winblad B., Bucht G., Gottfries G.C., Roos B.E. Monoamines and monoamine metabolites in brains from demented schizophrenics. Acta Psychiatr. Scand. 60:1979;17-28
112. Wing J.K. Clinical concepts of schizophrenia. Wing J.K. Schizophrenia; Towards a New Synthesis. 1978;1-30 Academic Press, London
113. Wise C.D., Stein L. Dopamine-β-hydroxylase deficits in the brains of schizophrenic patients. Science. 181:1973;344-347
114. Wise C.D., Stein L. Dopamine β-hydroxylase activity in brains of chronic schizophrenic patients. Science. 187:1975;370
115. Wise C.D., Baden M.M., Stein L. Postmortem measurement of enzymes in human brain: evidence of a central noradrenergic deficit in schizophrenia. J. Psychiatry Res. 11:1974;185-198
116. Witte E.A., Marrocco R.T. Alteration of brain noradrenergic activity in rhesus monkeys affects the alerting component of covert orienting. Psychopharmacology. 132:1997;315-323
117. Wolkins A., Sanfilipo M., Angrist B., Duncan E., Wieland S., Wolf A.P., Brodie J.D., Cooper T.B., Laska E., Rotrosen J.P. Acute D-amphetamine challenge in schizophrenia: effects on cerebral glucose utilization and clinical symptomatology. Biol. Psychiatry. 36:1994;317-325
118. Wyatt R.J., Schwartz M.A., Erdelyi E., Barchas J.D. Dopamine β-hydroxylase activity in brains of chronic schizophrenic patients. Science. 187:1975;368-369
119. Wyatt R.J., Potkin S.G., Kleinman J.E., Weinberger D.R., Luchins D.J. The schizophrenia syndrome. Examples of biological tools for subclassification. J. Nerv. Ment. Dis. 169:1981;100-112
120. Yamamoto K., Ozawa N. Increased firing of locus coeruleus neurons associated with preparatory set in rats. Neurosci. Lett. 106:1989;112-118
121. Yamamoto K., Arai H., Nakayama S. Skin conductance response after 6-hydroxydopamine lesion of the central noradrenergic system in cats. Biol. Psychiatry. 28:1990;151-160
122. Yamamoto K., Shinba T., Andou Y. An early relapse-treatment of schizophrenia with oxypertine. World Fed. Ment. Health, World Cong. Abst. 1993;185
123. Yamamoto K., Ozawa N., Shinba T., Andou Y., Hoshino T. Reproduction of psychophysiological signs in animals; implication for a noradrenaline hypothesis of schizophrenia. Moroji T., Yamamoto K. The Biology of Schizophrenia. 1994;135-156 Elsevier, Amsterdam
124. Yamamoto K., Ozawa N., Shinba T., Hoshino T. Functional influence of the central noradrenergic system on the skin conductance activity in rats. Schizophr. Res. 13:1994;145-150
125. Yamamoto K., Ozawa N., Shinba T., Hoshino T., Yoshii M. Possible noradrenergic dysfunction in schizophrenia. Brain Res. Bull. 35:1994;529-543
126. Yaryura-Jobias J.A., Diamond B., Merlis S. The action of L-dopa on schizophrenic patients (a preliminary report). Curr. Ther. Res. 12:1970;528-531
127. Yokoo H., Tanaka M., Tanaka T., Tsuda A. Stress-induced increase in noradrenaline release in the rat hypothalamus assessed by intracranial microdialysis. Experientia. 46:1990;290-292
128. Yorkston N.J., Zaki S.A., Weller M.P., Gruzelier J.H., Hirsch S.R. DL-Propranolol and chlorpromazine following admission for schizophrenia: a controlled comparison. Acta Psychiat. Scand. 63:1981;13-27